Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Ausun Pharmaceutical CoSHSE:603229 -1.08%83 Return-on-Tangible-Equity is 17.84% as of Mar. 2026, which is 50% above its 10-year median of 11.91. GuruFocus rates SHSE:603229 with a GF Score™ of 83/100 and a GF Value™ of ¥10.32 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 1,198 Biotechnology companies, Zhejiang Ausun Pharmaceutical Co ranks better than 81.72% on this metric.
The historical rank and industry rank for Zhejiang Ausun Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:603229'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.9 Med: 11.91 Max: 32.33
Current: 4.9
During the past 13 years, Zhejiang Ausun Pharmaceutical Co's highest Return-on-Tangible-Equity was 32.33%. The lowest was 4.90%. And the median was 11.91%.
SHSE:603229's Return-on-Tangible-Equity is ranked better than 81.72% of 1198
companies
in the Biotechnology industry
Industry Median: -42.305
vs SHSE:603229: 4.90
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Zhejiang Ausun Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Zhejiang Ausun Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Ausun Pharmaceutical Co Return-on-Tangible-Equity Chart
SHSE:603229 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Zhejiang Ausun Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Ausun Pharmaceutical Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhejiang Ausun Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Zhejiang Ausun Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 17.84% mean?
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) has a Return-on-Tangible-Equity of 17.84% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. This is 50% above median its historical median of 11.91. Over the past decade, Zhejiang Ausun Pharmaceutical Co's Return-on-Tangible-Equity has ranged from 4.90 to 32.33. According to the industry distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #219 out of 1198 companies in the Biotechnology industry, placing it in the top 18.3%.
Is Zhejiang Ausun Pharmaceutical Co's Return-on-Tangible-Equity too high?
Zhejiang Ausun Pharmaceutical Co's current Return-on-Tangible-Equity of 17.84% is 50% above median its 10-year median of 11.91. Over the past 10 years, this metric has ranged from a low of 4.90 to a high of 32.33. Based on the distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #219 out of 1198 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Ausun Pharmaceutical Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Ausun Pharmaceutical Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #219 out of 1198 companies for Return-on-Tangible-Equity. This places Zhejiang Ausun Pharmaceutical Co in the top 18% of its industry — outperforming the majority of peers. Historically, Zhejiang Ausun Pharmaceutical Co's own Return-on-Tangible-Equity has ranged from 4.90 to 32.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. Zhejiang Ausun Pharmaceutical Co's current Return-on-Tangible-Equity is 17.84%, which is 50% above median its own 10-year median of 11.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Ausun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co (SHSE:603229) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.32, compared to a current price of ¥7.32 — trading 29.1% below its estimated fair value. The current Return-on-Tangible-Equity is 17.84%, which is 50% above median its 10-year median of 11.91. Zhejiang Ausun Pharmaceutical Co's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Zhejiang Ausun Pharmaceutical Co (SHSE:603229), the current Return-on-Tangible-Equity is 17.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥7.32 is trading 29.1% below its estimated GF Value™ of ¥10.32.
GuruFocus considers Zhejiang Ausun Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603229:
Return-on-Tangible-Equity: 17.84% (50% above median its 10-year median of 11.91)
GF Value™: ¥10.32 vs. price of ¥7.32 (29.1% below fair value)
No single metric tells the full story. See the SHSE:603229 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Ausun Pharmaceutical Co Business Description
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
83GF Score
Get the complete analysis for SHSE:603229
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603229 has been successfully added to your 
